{'fraction_non_alphanumeric': 0.055970149253731345, 'fraction_numerical': 0.03731343283582089, 'mean_word_length': 4.707446808510638, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognostic value of matrix metalloproteinases (MMP‐2 and MMP‐9) in Hodgkin's and non‐Hodgkin's lymphoma

Matrix metalloproteinases (MMPs) are responsible for the degradation of extracellular matrix and have an important role in tumour metastases. We investigated the role of MMP‐2 and MMP‐9 in Hodgkin's disease (HD) and non‐Hodgkin's lymphoma (NHL).The serum samples of patients with HD (n = 12), NHL (n = 30) and healthy control (n = 22) were analysed for MMP‐2 and MMP‐9. An immunoassay method was used for the determination of MMP‐2 and MMP‐9 levels. No statistical significance was found between HD and NHL groups for levels of MMP‐2. There were no relation between MMP‐2, MMP‐9 levels and clinical characteristics of patients. The mean MMP‐9 levels were found to be 555.6 ± 140 ng/ml, 446.6 ± 53.6 ng/ml and 111.2 ± 10.3 ng/ml in HD, NHL and control groups, respectively. Our results suggest that MMP‐9 levels are substantially increased in HD and NHL when compared with controls and may probably be used for distinguishing the benign diseases from malign lymphomas.